Your browser doesn't support javascript.
loading
Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation.
Arte, Kinnari S; Tower, Cole W; Mutukuri, Tarun T; Chen, Yuan; Patel, Sajal M; Munson, Eric J; Tony Zhou, Qi.
Afiliación
  • Arte KS; Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
  • Tower CW; Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
  • Mutukuri TT; Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA; Injectable Drug Product Development, Alexion - AstraZeneca Rare Disease Unit, New Haven, CT 06510, USA(1).
  • Chen Y; Dosage Form Design & Development, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA; Global Product Quality, Global Quality Operations, AstraZeneca, Gaithersburg, MD 20787, USA(1).
  • Patel SM; Dosage Form Design & Development, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
  • Munson EJ; Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
  • Tony Zhou Q; Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA. Electronic address: tonyzhou@purdue.edu.
Int J Pharm ; 650: 123698, 2024 Jan 25.
Article en En | MEDLINE | ID: mdl-38081559
ABSTRACT
Pulmonary delivery of protein-based therapeutics, including antibodies, is a promising option for treating respiratory diseases. Spray drying is a widely used method for producing dry powder formulations with mannitol being a commonly used excipient for these inhalation formulations. There is limited research available concerning the utilization of mannitol as an excipient in the spray drying of proteins and its impact on aerosol performance. This study highlights the importance to understand mannitol's potential role and impact in this context. To investigate the impact of mannitol on physical stability and aerosolization of spray-dried protein formulations, bovine serum albumin (BSA) was employed as a model protein and formulated with different concentrations of mannitol via spray drying. The spray-dried solids were characterized for their particle size using Malvern mastersizer and aerodynamic particle size using next generation impactor (NGI). Additionally, the solids were characterized with solid-state Fourier-transform infrared spectroscopy (ssFTIR), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM) and solid-state nuclear magnetic resonance spectroscopy (ssNMR) to analyze the change in their secondary structure, crystallinity, particle morphology, and protein-excipient interaction, respectively. Size exclusion chromatography (SEC) was used to investigate changes in monomer content resulting from storage under stressed condition of 40 °C. Protein formulations containing more than 33 % mannitol by weight showed crystallization tendencies, causing an increase in monomer loss over time. ssNMR data also showed mixing heterogeneity of BSA and mannitol in the formulations with high mannitol contents. Futhermore, fine particle fraction (FPF) was found to decrease over time for the formulations containing BSA Mannitol in the ratios of 21, 12, and 15, due to particle agglomeration induced by crystallization of mannitol. This study underscores the significant influence of excipients such as mannitol on the aerosol performance and storage stability of spray-dried protein formulations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Excipientes / Manitol Idioma: En Revista: Int J Pharm Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Excipientes / Manitol Idioma: En Revista: Int J Pharm Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos